LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Начало・Списък с акции・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Затворен

4.29 -4.24

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.29

Максимум

4.33

Ключови измерители
By Trading Economics
Приходи	4M -3.8M
Продажби	522K 1.1M
EPS	-0.014
Марж на печалбата	-357.374
Служители	44
EBITDA	-1.1M -8.8M

Дивиденти
By Dow Jones
Следващи печалби	13.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	12M 851M
Предишно отваряне	8.53
Предишно затваряне	4.29

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

3.255 / 3.365 Подкрепа & съпротива

Arbutus Biopharma Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.03.2026 г., 17:33 ч. UTC

Значими събития в новините

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27.03.2026 г., 17:00 ч. UTC

Значими събития в новините

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27.03.2026 г., 16:03 ч. UTC

Значими събития в новините

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29.03.2026 г., 23:47 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls Amid Rising Inflation Fears -- Market Talk

29.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29.03.2026 г., 23:23 ч. UTC

Пазарно говорене

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29.03.2026 г., 22:34 ч. UTC

Пазарно говорене

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29.03.2026 г., 22:09 ч. UTC

Пазарно говорене

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29.03.2026 г., 21:06 ч. UTC

Пазарно говорене

Значими събития в новините

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29.03.2026 г., 21:03 ч. UTC

Пазарно говорене

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29.03.2026 г., 21:01 ч. UTC

Пазарно говорене

Значими събития в новините

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29.03.2026 г., 09:30 ч. UTC

Придобивния, сливания и поглъщания

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28.03.2026 г., 08:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 19:16 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27.03.2026 г., 19:07 ч. UTC

Пазарно говорене

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27.03.2026 г., 19:04 ч. UTC

Пазарно говорене

Gold Rises But Can't Finish the Week Positive -- Market Talk

27.03.2026 г., 19:03 ч. UTC

Пазарно говорене

Значими събития в новините

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 19:02 ч. UTC

Пазарно говорене

Значими събития в новините

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27.03.2026 г., 18:12 ч. UTC

Пазарно говорене

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27.03.2026 г., 17:36 ч. UTC

Значими събития в новините

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27.03.2026 г., 17:34 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27.03.2026 г., 17:29 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27.03.2026 г., 16:38 ч. UTC

Пазарно говорене

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27.03.2026 г., 16:32 ч. UTC

Пазарно говорене

Значими събития в новините

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27.03.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.03.2026 г., 15:43 ч. UTC

Пазарно говорене

Значими събития в новините

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.03.2026 г., 15:25 ч. UTC

Пазарно говорене

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arbutus Biopharma Corp Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Arbutus Biopharma Corp през последните 3 месеца.

Техническа оценка

By Trading Central

3.255 / 3.365Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.